Statement: FDA Must Reject Tanezumab as a Treatment for Osteoarthritis Due to Unacceptable Dangers, Little to No Benefit
Undemocratic WTO Processes Produce Shameful Result on Intellectual Property and Covid at 12th WTO Ministerial
U.S. Pharmaceutical Corporation Uses NAFTA Foreign Investor Privileges Regime to Attack Canada’s Patent Policy, Demand $100 Million for Invalidation of a Patent March 1, 2017
Fact Sheet: NAFTA’s Legacy: Expanding Corporate Power to Attack Public Interests Laws and Outsource Jobs September 1, 2019
Fact Sheet: NAFTA’s Legacy: Expanding Corporate Power to Attack Public Interest Laws October 12, 2018